Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Subhashis Banerjee

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
Biorxiv : the Preprint Server for Biology|February 6, 2026
Dual Lineage Tracing Identifies Cellular Mechanisms Underlying Radiation-Associated Changes in Atherosclerotic Lesion CompositionRebecca A Deaton, Tajbir Raihan, Victoria M Milosek, et al.
JAMA Dermatology|December 20, 2023
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical TrialKim A Papp, Kenneth Gordon, Bruce Strober, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled TrialEric Morand, Marilyn Pike, Joan T Merrill, et al.
The Journal of Allergy and Clinical Immunology|June 9, 2012
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasisJames G Krueger, Scott Fretzin, Mayte Suárez-Fariñas, et al.
The British Journal of Dermatology|October 22, 2024
Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trialJianzhong Zhang, Yangfeng Ding, Ping Wang, et al.
Dermatology and Therapy|July 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Expert Opinion on Investigational Drugs|May 29, 2024
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosusEric F Morand, Marilyn Pike, J Merrill, et al.
Dermatology and Therapy|March 6, 2025
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Journal of the American Academy of Dermatology|December 20, 2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasisAndrew Blauvelt, Phoebe Rich, Howard Sofen, et al.
Nature Communications|December 24, 2014
Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviourSubhashis Banerjee, Yongjun Wang, Laura A Solt, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
Biorxiv : the Preprint Server for Biology|February 6, 2026
Dual Lineage Tracing Identifies Cellular Mechanisms Underlying Radiation-Associated Changes in Atherosclerotic Lesion CompositionRebecca A Deaton, Tajbir Raihan, Victoria M Milosek, et al.
JAMA Dermatology|December 20, 2023
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical TrialKim A Papp, Kenneth Gordon, Bruce Strober, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled TrialEric Morand, Marilyn Pike, Joan T Merrill, et al.
The Journal of Allergy and Clinical Immunology|June 9, 2012
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasisJames G Krueger, Scott Fretzin, Mayte Suárez-Fariñas, et al.
The British Journal of Dermatology|October 22, 2024
Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trialJianzhong Zhang, Yangfeng Ding, Ping Wang, et al.
Dermatology and Therapy|July 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Expert Opinion on Investigational Drugs|May 29, 2024
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosusEric F Morand, Marilyn Pike, J Merrill, et al.
Dermatology and Therapy|March 6, 2025
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Journal of the American Academy of Dermatology|December 20, 2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasisAndrew Blauvelt, Phoebe Rich, Howard Sofen, et al.
Nature Communications|December 24, 2014
Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviourSubhashis Banerjee, Yongjun Wang, Laura A Solt, et al.
Pageof 12